Clinical data
ATC code None
CAS Number 872363-17-2
PubChem (CID) 44557636
ChemSpider 25069676
Chemical and physical data
Formula C16H12FN3
Molar mass 265.285 g/mol
3D model (Jmol) Interactive image

Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]

See also


  1. 1 2 Ana Martinez; Carmen Gil (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
  2. John E. Macor (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
  3. Susan H. Fox; Jonathan M. Brotchie (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
  4. Addex Therapeutics. "Dipraglurant-ER for dystonia".

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.